NCT01896739已完成3 期
A Multicentre, Comparative, Open-label, Randomized, Phase III Study to Assess the Immunogenicity and Safety of EutravacTMinj (DTaP-HB Combined Vaccine) Administered at 2,4, 6 Months of Age Compared With DTaP Vaccine at 2, 4, 6 Months of Age Combined Administered Monovalent Hepatitis B Vaccine Administered at Birth, 1, 6 Months of Age in Healthy Infants.
LG Life Sciences14 个研究点 分布在 1 个国家目标入组 289 人开始时间: 2009年8月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 289
- 试验地点
- 14
- 主要终点
- Seroprotection rate
研究概览
简要总结
To evaluate and compare the immunogenicity of Eutravac (Diphtheria-Tetanus-acellular Pertussis [DTaP] Hepatitis B [HB] combined) vaccine with separate but simultaneous administrations of DTaP and HB vaccine each administered to healthy infants, as measured by seroprotection/vaccine response rates 4-8 weeks post-final immunisation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- — 至 6 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Were healthy, male or female infants born at full term pregnancy (≥37 weeks) with a birth weight ≥2.5 kg to mothers with a negative HBsAg serology, documented prior to giving birth as per routine, site-specific ante-natal care procedures.
- •Signed parental or legally acceptable representative's informed consent was obtained
排除标准
- •Evidence of an acute febrile illness with axillary temperature ≥37.5℃ on the day of the vaccination. Infants with symptoms of minor illness eg, mild gastroenteritis, mild upper respiratory tract infection and who did not have a temperature ≥37.5℃ on the day of the vaccination could be included at the Investigator's discretion
- •History of diphtheria, tetanus, pertussis or hepatitis B disease
- •History of any vaccine-related hypersensitivity or anaphylactic reaction after previous administration of Euvax B
结局指标
主要结局
Seroprotection rate
时间窗: After final immunisation at 4-8 weeks
次要结局
未报告次要终点
研究者
研究点 (14)
Loading locations...
相似试验
已完成
3 期
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of AgeMeaslesPolioTetanusDiphtheriaPertussisNCT01346293Sanofi Pasteur, a Sanofi Company3,372
已完成
3 期
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruSPoliomyelitisPertussisTetanusDiphtheriaNCT02458183Boryung Pharmaceutical Co., Ltd476
已完成
3 期
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT02545868Hoffmann-La Roche102
已完成
3 期
Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to AdultsHealthyNCT01033877Statens Serum Institut802
已完成
4 期
Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)Rotavirus DiseaseNCT01926015Merck Sharp & Dohme LLC192